Michael Hallek
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber P, Tadmor T, Levin M, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling E, Lindstrom V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink A, Fischer K, Wendtner C, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann C, Hallek M, Eichhorst B, Kreuzer K, Kater A. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 2023
12.05.2023High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
12.05.2023Blood 2023
Fürstenau Moritz, Thus Yvonne J, Robrecht Sandra, Mellink Clemens H M, van der Kevie-Kersemaekers Anne-Marie F, Dubois Julie, von Tresckow Julia, Patz Michaela, Gregor Michael, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Levin Mark-David, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Janssens Ann, Christiansen Ilse, Noesslinger Thomas, Baumann Michael, Hebart Holger, Gaska Tobias, Regelink Josien, Dompeling Ellen C, Lindstrom Vesa, Juliusson Gunnar, Widmer Anouk Andrea, Goede Jeroen, Goldschmidt Neta, Simon Florian, De Silva Nisha, Fink Anna Maria, Fischer Kirsten, Wendtner Clemens-Martin, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Spaargaren Marcel, Eldering Eric, Stilgenbauer Stephan, Niemann Carsten Utoft, Hallek Michael, Eichhorst Barbara, Kreuzer Karl-Anton, Kater Arnon P
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber P, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Noesslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, Klift M, Jäger U, Leys M, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink J, Widmer A, Simon F, De Silva N, Fink A, Bahlo J, Fischer K, Wendtner C, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Levin M, van Oers M, Geisler C, Stilgenbauer S, Hallek M, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:1739-1754.
11.05.2023First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
11.05.2023N Engl J Med 2023; 388:1739-1754
Eichhorst Barbara, Niemann Carsten Utoft, Kater Arnon P, Fürstenau Moritz, von Tresckow Julia, Zhang Can, Robrecht Sandra, Gregor Michael, Juliusson Gunnar, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Lindstrom Vesa, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Noesslinger Thomas, Janssens Ann, Christiansen Ilse, Baumann Michael, Frederiksen Henrik, Klift Marjolein van der, Jäger Ulrich, Leys Maria B L, Hoogendoorn Mels, Lotfi Kourosh, Hebart Holger, Gaska Tobias, Koene Harry, Enggaard Lisbeth, Goede Jereon, Regelink Josien, Widmer Anouk Andrea, Simon Florian, De Silva Nisha, Fink Anna Maria, Bahlo Jasmin, Fischer Kirsten, Wendtner Clemens-Martin, Kreuzer Karl A, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Levin Mark-David, van Oers Marinus, Geisler Christian, Stilgenbauer Stephan, Hallek Michael, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland
Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner C, Klein C, Liu N, Hallek M, Frenzel L, Krause G. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer 2015; 137:2234-42.
12.05.2015Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
12.05.2015Int J Cancer 2015; 137:2234-42
Göckeritz Elisa, Kerwien Susan, Baumann Michael, Wigger Marion, Vondey Verena, Neumann Lars, Landwehr Thomas, Wendtner Clemens M, Klein Christian, Liu Ningshu, Hallek Michael, Frenzel Lukas P, Krause Günter
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Behringer K, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause S, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, Bentz M, Vieler T, Kriz J, Goergen H, Tanner A, Zijlstra J, Greil R, Markova J, Sasse S, Fuchs M, Topp M, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2014; 385:1418-27.
22.12.2014Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
22.12.2014Lancet 2014; 385:1418-27
Behringer Karolin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Bentz Martin, Vieler Tom, Kriz Jan, Goergen Helen, Tanner Antonia, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert
B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.
Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch C, Hallek M, Wendtner C, Frenzel L. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 2012; 120:3978-85.
27.08.2012B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.
27.08.2012Blood 2012; 120:3978-85
Schwamb Janine, Feldhaus Valeska, Baumann Michael, Patz Michaela, Brodesser Susanne, Brinker Reinhild, Claasen Julia, Pallasch Christian P, Hallek Michael, Wendtner Clemens-Martin, Frenzel Lukas P